Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
PTC-844 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
PTC-844: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
GDD-3898 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
GDD-3898: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
Umbilical cord mesenchymal stem cell(Changhai Hospital) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Umbilical cord mesenchymal stem cell(Changhai Hospital): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.
8 min read
ETD-001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
ETD-001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
BC-006 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
BC-006: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
SYS6023 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
SYS6023: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
68GaNOTA-Anti-MMR-VHH2(Universitair Ziekenhuis Brussel): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.
8 min read
LX-22001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
LX-22001: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
CT102 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
CT102: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
VB19055 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
VB19055: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
8 min read
LY-3537021 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
LY-3537021: Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key.
8 min read
Dendritic cell vaccine(Medigene Immunotherapies GmbH) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
11 September 2026
Dendritic cell vaccine(Medigene Immunotherapies GmbH): Phase 2. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP.